Isis Pharmaceuticals Announces Open-Label Extension Study SHINE in Pediatric SMA Patients
Isis Pharmaceuticals, Inc. recently announced the official launch of an open-label extension study, called SHINE, which will be continuing treatment of the same infants and children diagnosed with spinal muscular atrophy (SMA) who had previously…